Alnylam Pharmaceuticals has added three new members to its management team.
Philip Chase has been named vice president of legal, Eric Raichle has been named vice president of human resources, and Jason Rhodes has been named vice president of business development.
Chase most recently served as vice president and general counsel at RenaMed Biologics. He holds a JD from Columbia University School of Law.
Raichle joins Alnylam from Alkermes, where he was director of human resources. He holds a BA in industrial and organizational psychology from SuffolkUniversity.
Rhodes was most recently a partner at biotech venture capital firm Fidelity Biosciences, and he holds an MBA from the Wharton School of the University of Pennsylvania and a BA in history from YaleUniversity.
Merck said this week that it has named David Kelley as vice president and franchise integrator for diabetes and obesity.
Kelley joins Merck from the University of Pittsburgh where he most recently was professor of medicine and director of the university’s Obesity and Nutrition Research Center.
At Merck, Kelley will oversee the lead researchers for experimental medicine, imaging, and molecular profiling, and be responsible for coordinating all biomarker, experimental medicine, and imaging activities.
Kelley holds an MD from the University of Maryland School of Medicine.